Rotavirus News and Research

Latest Rotavirus News and Research

FDA recommends clinicians temporarily suspend use of Rotarix vaccine

The agency recently became aware that an independent U.S. academic research team, using a novel technique, has found DNA from porcine circovirus 1 (PCV1) in Rotarix, which is manufactured by GlaxoSmithKline. PCV1 is not known to cause illness in humans or other animals. In addition, Rotarix has been studied extensively, before and after approval, and found to have an excellent safety record.

24 Mar 2010

WHO advises continued use of GSK's rotavirus vaccine in developing countries

The WHO on Monday advised developing countries to continue administering GlaxoSmithKline's Rotarix vaccine - which offers protection to children against the diarrhea-causing rotavirus - after the FDA advised doctors in the U.S. to temporarily stop using the vaccine following the discovery that it was "contaminated with an apparently harmless pig virus," Reuters reports

24 Mar 2010

Temporary suspension of Rotarix – a rotavirus vaccine for kids

The US FDA after deliberation has come up with a warning to the nation’s pediatricians to stop giving children a vaccine that prevents diarrhea causing Rotavirus vaccine. There is reportedly a contamination with a harmless pig virus in this vaccine called Rotarix and manufactured by GlaxoSmithKline.

23 Mar 2010

GSK notifies regulatory authorities of the presence of PCV-1 in Rotarix vaccine

GlaxoSmithKline today confirmed that it has notified regulatory authorities of the presence of material from a virus called PCV-1 in its oral rotavirus vaccine, Rotarix™. PCV-1 does not multiply in humans and is not known to cause illness in humans.

23 Mar 2010

Nature News examines GAVI Alliance's budget gap

Nature News examines GAVI Alliance's multi-billion-dollar budget shortfall ahead of a donors meeting in The Hague on March 25-26.

18 Mar 2010

GAVI calls meeting with existing, potential donors

The GAVI Alliance has "asked existing and potential donors to a meeting in The Hague on March 25 and 26 to challenge them to 'make a strong impact' on childhood death rates," Reuters reports. "GAVI, which is supported by the World Health Organization, the World Bank, UNICEF, the Bill & Melinda Gates Foundation and vaccine makers, says it has 40 percent of the $7 billion it needs between now and 2015 to help" immunize of millions of children in developing countries by 2015, according to the news service.

16 Mar 2010

WHO welcomes Gates Foundation support in advancing global vaccine efforts

WHO welcomes the Bill & Melinda Gates Foundation pledge of US$ 10 billion over the next ten years to accelerate global vaccine efforts.

12 Mar 2010

Lancet World Report examines GAVI's funding gap

Lancet World Report examines the challenges ahead for the GAVI Alliance, which after a decade of "steadily increasing financing" is now "facing a funding shortfall for the next decade that could hamper the roll-out of new vaccines." GAVI leaders attribute the funding challenges to the global economic crisis, which has kept government aid budgets from increasing, according to the Lancet.

6 Mar 2010

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Commenting on the Group's 2009 performance, sanofi-aventis Chief Executive Officer Christopher A. Viehbacher said, "2009 was the first year of implementation of our new strategy. Major steps have already been achieved in strengthening our growth platforms and reinforcing our R&D pipeline while delivering a double-digit EPS(1) growth".

10 Feb 2010

Breakthrough discovery could help in developing a broad spectrum of antiviral drugs

Within a virus's tiny exterior is a store of energy waiting to be unleashed. When the virus encounters a host cell, this pent-up energy is released, propelling the viral DNA into the cell and turning it into a virus factory.

6 Feb 2010

WHO pneumonia expert honored with PACE Global Leadership Award

WHO pneumonia expert Dr. Thomas Cherian will be honored by a group of the world’s leading infectious disease experts today for his pivotal work to accelerate access to vaccines preventing pneumococcal disease, the world’s leading vaccine-preventable killer of children under age five.

31 Jan 2010

PATH praises Gates Foundation for supporting vaccine development and delivery

Vaccination may be the most effective public health intervention of all time-especially in low-income countries, where many families can't access or afford health care when they are sick. On Friday, January 29, speaking at the World Economic Forum in Davos, Switzerland, Bill and Melinda Gates announced a new ten-year Gates Foundation commitment to funding vaccine development and delivery.

30 Jan 2010

At World Economic Forum, Gates Foundation announces 10-year, $10B vaccine commitment

Bill and Melinda Gates announced Friday during the World Economic Forum in Davos, Switzerland, that their foundation would commit $10 billion over the next decade to research, develop and deliver vaccines for the world's poorest countries, the New York Times reports (McNeil, 1/29). The Gateses "said they hope the commitment would spur support by governments, corporations, and other donors for vaccinations efforts," the Chronicle of Philanthropy writes (Wilhelm, 1/29).

30 Jan 2010

Bill & Melinda Gates Foundation commits $10 billion for vaccine research and development

Bill and Melinda Gates announced today that their foundation will commit $10 billion over the next 10 years to help research, develop and deliver vaccines for the world's poorest countries.

29 Jan 2010

Rotavirus vaccine could save millions of children in developing countries, studies find

Efforts to vaccinate "infants against rotavirus could save the lives of millions of children in developing nations who would otherwise die from the diarrhea-causing disease, two new studies show," HealthDay/BusinsessWeek reports.

28 Jan 2010

Studies in Mexico and Africa demonstrate the effectiveness of rotavirus vaccine

For the first time ever, studies in Mexico and Africa, published today in the New England Journal of Medicine, demonstrate a reduction in diarrheal disease deaths following rotavirus vaccine introduction in Mexico and vaccine efficacy among impoverished populations in Malawi and South Africa.

28 Jan 2010

Gates annual letter addresses importance of innovation for global health, agriculture

In his second annual letter, Bill Gates reflects on the Bill & Melinda Gates Foundation's work and the importance innovation will play in overcoming some of the world's greatest challenges, including in global health and agriculture, the Associated Press reports. "Gates says the foundation currently is backing 30 areas of innovation including online learning, teacher improvement, malaria vaccine development, HIV prevention, and genetically modified seeds," according to the news service (Gordon Blankinship, 1/25).

27 Jan 2010

New study indicates appendicitis may be caused by viral infection

The researchers evaluated data over a 36-year period from the National Hospital Discharge Survey and concluded in a paper appearing in the January issue of Archives of Surgery that appendicitis may be caused by undetermined viral infection or infections, said Dr. Edward Livingston, chief of GI/endocrine surgery at UT Southwestern and senior author of the report.

19 Jan 2010

Opinions: U.S. medical emergency response; micronutrients; rotavirus vaccine; antibiotic development

"[D]espite the tireless efforts of public health and health-care workers, America's experience with H1N1 shows that the nation is not prepared to deal with a flu pandemic," former Democratic Senator Bob Graham and former Republican Senator Jim Talent write in Washington Post opinion piece that examines U.S. preparedness for medical emergencies. The writers chaired the Commission on the Prevention of Weapons of Mass Destruction Proliferation and Terrorism.

6 Jan 2010

National Vaccine Plan aims to protect Americans from vaccine-preventable illnesses

While vaccines help prevent many diseases in the United States, we lack immunization protection against several serious illnesses, says a new report from the Institute of Medicine that identifies priority areas for updating the National Vaccine Plan.

14 Dec 2009

Rotavirus News and Research

Latest Rotavirus News and Research

FDA recommends clinicians temporarily suspend use of Rotarix vaccine

WHO advises continued use of GSK's rotavirus vaccine in developing countries

Temporary suspension of Rotarix – a rotavirus vaccine for kids

GSK notifies regulatory authorities of the presence of PCV-1 in Rotarix vaccine

Nature News examines GAVI Alliance's budget gap

GAVI calls meeting with existing, potential donors

WHO welcomes Gates Foundation support in advancing global vaccine efforts

Lancet World Report examines GAVI's funding gap

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Breakthrough discovery could help in developing a broad spectrum of antiviral drugs

WHO pneumonia expert honored with PACE Global Leadership Award

PATH praises Gates Foundation for supporting vaccine development and delivery

At World Economic Forum, Gates Foundation announces 10-year, $10B vaccine commitment

Bill & Melinda Gates Foundation commits $10 billion for vaccine research and development

Rotavirus vaccine could save millions of children in developing countries, studies find

Studies in Mexico and Africa demonstrate the effectiveness of rotavirus vaccine

Gates annual letter addresses importance of innovation for global health, agriculture

New study indicates appendicitis may be caused by viral infection

Opinions: U.S. medical emergency response; micronutrients; rotavirus vaccine; antibiotic development

National Vaccine Plan aims to protect Americans from vaccine-preventable illnesses

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Rotavirus News and Research

Latest Rotavirus News and Research

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Newsletters you may be interested in